High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer.

about

At cancer diagnosis: a 'window of opportunity' for behavioural change towards physical activity. A randomised feasibility study in patients with colon and breast cancer

P2860

Q37293242-6E492A1F-2260-4F0E-8DE8-4C16D9EB3BC0

P2860

High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer.

Item

http://www.wikidata.org/entity/Q35623087

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

High rate of extra-haematologi ...... hemotherapy for breast cancer.

@ast

High rate of extra-haematologi ...... hemotherapy for breast cancer.

@en

type

Item

label

High rate of extra-haematologi ...... hemotherapy for breast cancer.

@ast

High rate of extra-haematologi ...... hemotherapy for breast cancer.

@en

prefLabel

High rate of extra-haematologi ...... hemotherapy for breast cancer.

@ast

High rate of extra-haematologi ...... hemotherapy for breast cancer.

@en

P1476

High rate of extra-haematologi ...... hemotherapy for breast cancer.

@en

P2093

A L Martin

http://www.w3.org/2001/XMLSchema#string

B Asselain

http://www.w3.org/2001/XMLSchema#string

C Levy

http://www.w3.org/2001/XMLSchema#string

C Veyret

http://www.w3.org/2001/XMLSchema#string

D Serin

http://www.w3.org/2001/XMLSchema#string

E Brain

http://www.w3.org/2001/XMLSchema#string

F Bonnetain

http://www.w3.org/2001/XMLSchema#string

H Roché

http://www.w3.org/2001/XMLSchema#string

L Mauriac

http://www.w3.org/2001/XMLSchema#string

M Gauthier

http://www.w3.org/2001/XMLSchema#string

P2860

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.

A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer.

Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer.

Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer.

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

P2888

bjc.2011.414

P304

1480-1486

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2011.414

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51726852

http://www.w3.org/2001/XMLSchema#string

P698

22009030

http://www.w3.org/2001/XMLSchema#string

P932

3242527

http://www.w3.org/2001/XMLSchema#string

High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer.

about

P2860

P2860

High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932